High-Intensity Interval Exercise in Bronchiectasis Patients
2026年9月3日 更新者：Saglik Bilimleri Universitesi
Investigation of the Effectiveness of High-Intensity Interval Exercise in Bronchiectasis Patients
The aim of our study is to investigate the effect of high-intensity interval exercise (HIIE) on the symptoms of bronchiectasis in patients with the disease. The main questions it aims to answer are:
- Does HIIE improve respiratory function in patients with bronchiectasis?
- Does HIIE increase functional capacity, peripheral muscle strength, and quality of life in patients with bronchiectasis?
- Does HIIE reduce the severity of dyspnea, cough symptoms, and fatigue in patients with bronchiectasis?
The study was designed as a randomized controlled trial. Participants were divided into two groups: intervention and control.
Participants will:
The intervention group will receive HIIE training three days a week along with airway clearance techniques.
The control group would receive only airway clearance techniques. Airway clearance techniques will be provided clinically (three days a week) and at home, according to the needs of the individuals each day of the week.
調査の概要
状態
募集
研究の種類
介入
入学 (推定)
42
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Mustafa Ertuğrul YAŞA, Associate Professor
- 電話番号：0312 304 61 97
- メール：mustafaertugrul.yasa@sbu.edu.tr
研究場所
-
-
Keçiören
-
Ankara、Keçiören、トルコ（Türkiye）、06018
- 募集
- Gulhane Faculty of Physiotherapy and Rehabilitation
-
コンタクト：
- 電話番号：0 312 567 15 00
- メール：bilgiedinme@sbu.edu.tr
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
はい
説明
Inclusion Criteria:
- Being over 18 years of age
- Having a clinical and radiological diagnosis of non-cystic fibrosis bronchiectasis
- Absence of cognitive impairment (MMT>24)
- Being clinically stable (not having experienced any exacerbation in the last 4 weeks)
Exclusion Criteria:
- Presence of any disease that may affect compliance with exercise (Unstable angina (within the last month), recent myocardial infarction (heart attack), uncontrolled arrhythmias, severe aortic stenosis, decompensated heart failure, severe pulmonary hypertension, acute respiratory tract infection, severe hypoxemia at rest (<85%), orthopedic or neurological problems that impede walking, severe anemia, acute infections, very high resting blood pressure (systolic >180-200 mmHg, diastolic >100-110 mmHg), psychological issues, etc.)
- Smoking
- Chronic alcoholism that may affect exercise safety (More than 1 drink per day on average for women, more than 2 drinks per day on average for men (1 standard drink ≈ 10-14 g of alcohol)
- Presence of any respiratory tract disease other than bronchiectasis
- After incremental shuttle walk test arterial oxygen saturation <80%
- Participation in a structured exercise program within the last 6 months
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Intervention
Patients in this group will perform airway clearance techniques along with high-intensity interval exercise.
|
The high-intensity interval exercise (HIIE) protocol (4×4 model: 4 minutes at 85-95% maximum heart rate, with 3 minutes of active recovery at 60-70% in between), will be applied 3 days a week for 8 weeks using a treadmill or cycle ergometer, taking into account the participants' physical characteristics and safety requirements.
Among the airway clearance techniques, the active cycle of breathing techniques (ACBT) and manual techniques will be applied.
Additionally, the autogenic drainage technique will be taught to patients for them to practice at home.
Airway clearance techniques will be demonstrated to the patients practically and they will be asked to perform them daily (3 days a week in the clinic) as needed.
|
|
アクティブコンパレータ：Control
Patients in this group will only undergo airway clearance techniques.
|
Among the airway clearance techniques, the active cycle of breathing techniques (ACBT) and manual techniques will be applied.
Additionally, the autogenic drainage technique will be taught to patients for them to practice at home.
Airway clearance techniques will be demonstrated to the patients practically and they will be asked to perform them daily (3 days a week in the clinic) as needed.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Functional Performance
時間枠：At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
Functional performance will be measured using an incremental shuttle walk test.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximal Inspiratory Pressure (PImax)
時間枠：At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Inspiratory muscle strength will be assessed by measuring the maximal inspiratory pressure (PImax) using an electronic, portable, intraoral pressure measuring device.
PImax represents the maximum negative pressure generated during a forceful inhalation against an occluded airway.
Results will be reported in centimeters of water (cmH2O), with higher absolute values indicating greater inspiratory muscle strength.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
|
Maximal Expiratory Pressure (PEmax)
時間枠：At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Expiratory muscle strength will be assessed by measuring the maximal expiratory pressure (PEmax) using an electronic, portable, intraoral pressure measuring device.
PEmax represents the maximum positive pressure generated during a forceful exhalation against an occluded airway.
Results will be reported in centimeters of water (cmH2O), with higher values indicating greater expiratory muscle strength.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
|
Forced Vital Capacity (FVC)
時間枠：At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Forced Vital Capacity (FVC) is the total volume of air that can be exhaled forcefully and completely after a maximal inspiration.
It is measured using spirometry to assess overall lung volume and capacity.
The results will be reported as an absolute volume in Liters (L).
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
|
FEV1 (Forced Expiratory Volume in 1 Second)
時間枠：At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Forced Expiratory Volume in 1 second (FEV1) is the volume of air forcefully exhaled during the first second after a maximal inspiration, measured using spirometry.
Outcomes are reported in absolute volume (Liters) and % to evaluate airway obstruction and overall pulmonary function.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
|
FEV1/FVC
時間枠：At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
FEV1/FVC(%) will be calculated using the FEV1 and FVC values obtained from the pulmonary function test.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
|
Fatigue
時間枠：At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
To assess the severity of fatigue and its impact on daily life, the Fatigue Severity Scale (FSS), a self-report scale, will be used.
The scale consists of 9 items, each scored between 1 (strongly disagree) and 7 (strongly agree).
The average score is calculated by dividing the total score by the number of items, with higher scores indicating more severe fatigue.
A score of 4 or higher generally indicates severe fatigue.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
|
Dyspnea Severity
時間枠：At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
Dyspnea severity will be assessed using the Modified Medical Research Council dyspnea scale.
The scale classifies dyspnea on a five-point scale from 0 to 4; a score of 0 indicates dyspnea occurring only during strenuous exercise, while a score of 4 describes significant shortness of breath even during the mildest daily activities.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
|
The Bronchiectasis Health Questionnaire
時間枠：At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
The Bronchiectasis Health Questionnaire (BHQ) will be used to assess disease-specific quality of life.
The BHQ is a patient-completed scale consisting of 10 items that evaluates symptom burden, physical function, and the impact of the disease on daily life.
Each item is scored between 0 and 7, and the total score ranges from 0 to 70; higher scores indicate better health status and quality of life.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study
|
|
Cough Questionnaire
時間枠：At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
The Leicester Cough Questionnaire (LCQ) is a disease-specific, patient-completed scale developed to assess the impact of cough on quality of life in individuals with chronic cough.
The LLC consists of 19 items and covers three sub-dimensions: physical, psychological, and social.
Each item is scored between 1 and 7, and the average of the sub-dimension scores is calculated and summed to obtain a total score ranging from 3 to 21; higher scores indicate better quality of life and less cough-related impact.
|
At the beginning of the study, after 8 weeks of treatment, and at week 4 following the study.
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2026年3月27日
一次修了 (推定)
2026年12月31日
研究の完了 (推定)
2027年5月29日
試験登録日
最初に提出
2026年4月21日
QC基準を満たした最初の提出物
2026年9月3日
最初の投稿 (実際)
2026年9月4日
学習記録の更新
投稿された最後の更新 (実際)
2026年9月4日
QC基準を満たした最後の更新が送信されました
2026年9月3日
最終確認日
2026年4月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2026-085
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
IPD プランの説明
Due to patient confidentiality, data will not be shared.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。